Clinical Trials

470 enrolled

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06191744 2026-04-13

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT06508658 2026-04-08

EPCORE DLBCL-4

379 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06084936 2026-04-02

GLOBRYTE

182 enrolled

Lymphoma

NCT04824092 2026-04-01

frontMIND

899 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05100862 2026-03-18

MAHOGANY

780 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence

NCT04404283 2026-03-17

ECHELON-3

238 enrolled 3 FDA

Lymphoma, Large B-Cell, Diffuse

NCT04224493 2026-03-02

SYMPHONY-1

612 enrolled

Lymphoma, Follicular

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

514 enrolled

LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT04712097 2026-02-04

Celestimo

478 enrolled

Phase 3 Not yet recruiting

Lymphoma, Follicular, Recurrence

NCT07355283 2026-01-27

IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma

198 enrolled

Lymphoma, Follicular

NCT06220032 2026-01-05

HO170DLBCL

324 enrolled

LymphoidSarcoma

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity

NCT04680052 2025-12-22

InMIND

654 enrolled 40 charts 3 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06006117 2025-12-19

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

260 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT05429268 2025-12-10

firmMIND

82 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06911502 2025-12-05

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled

Lymphoma, Follicular

NCT02390869 2025-12-02

FIL_RENOIR12

128 enrolled

Lymphoma, Follicular, Recurrence

NCT05371093 2025-10-15

ZUMA-22

231 enrolled

Lymphoma, Follicular

NCT01650701 2025-09-25

RELEVANCE

1,030 enrolled

Lymphoma, Follicular

NCT06082102 2025-09-15

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

324 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT05409066 2025-07-28

EPCORE FL-1

549 enrolled 5 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT01996865 2025-07-10

MAGNIFY

503 enrolled 18 charts 2 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01476787 2025-05-14

RELEVANCE

1,030 enrolled 12 charts

Lymphoma, Follicular

NCT01865110 2025-03-05

R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

623 enrolled

Lymphoma, Mantle-Cell

NCT06284122 2024-10-15

MorningLyte

790 enrolled

Lymphoma, Follicular

NCT06522555 2024-08-05

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

100 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02285062 2023-06-22

ROBUST

570 enrolled 27 charts

Limb-girdle muscular dystrophy, type 2C, Lymphoma, Large B-Cell, Diffuse

NCT05179733 2023-05-23

The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years

Phase 3 Unknown

280 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05351346 2023-03-24

Genotype-guided Treatment in DLBCL

1,100 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01938001 2023-02-22

AUGMENT

358 enrolled 18 charts 2 FDA

Lymphoma, Non-Hodgkin

NCT01239797 2022-06-01

ELOQUENT - 2

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT01556776 2022-01-05

A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

LymphoidOther hematologic neoplasm

89 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00774345 2021-12-02

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

LymphoidOther hematologic neoplasm

317 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01122472 2021-07-26

REMARC

650 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT02128061 2021-04-13

Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+

250 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01021423 2019-11-19

RENEW

Phase 3 Terminated

9 enrolled 10 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT00910910 2019-07-09

ORIGIN

LymphoidOther hematologic neoplasm

450 enrolled 25 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01098656 2018-07-09

Lenalidomide Maintenance Post-debulking in Advanced CTCL

Phase 3 Terminated

21 enrolled

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT02354313 2018-02-09

MCL0208

Phase 3 Unknown

300 enrolled